Chemotherapy-induced peripheral neuropathy (CIPN) is a serious adverse side effect of many chemotherapeutic agents, affecting >60% of patients with cancer. Moreover, CIPN persists long into survivorship in approximately 20% to 30% of these patients. To the authors' knowledge, no drugs have been approved to date by the US Food and Drug Administration to effectively manage chemotherapy-induced neuropathic pain. The majority of the drugs tested for the management of CIPN aim at symptom relief, including pain and paresthesia, yet are not very efficacious. The authors propose that there is a need to acquire a more thorough understanding of the etiology of CIPN so that effective, mechanism-based, disease-modifying interventions can be developed. It is important to note that such interventions should not interfere with the antitumor effects of chemotherapy. Mitochondria are rodshaped cellular organelles that represent the powerhouses of the cell, in that they convert oxygen and nutrients into the cellular energy "currency" adenosine triphosphate. In addition, mitochondria regulate cell death. Neuronal mitochondrial dysfunction and the associated nitro-oxidative stress represent crucial final common pathways of CIPN. Herein, the authors discuss the potential to prevent or reverse CIPN by protecting mitochondria and/or inhibiting nitro-oxidative stress with novel potential drugs, including the mitochondrial protectant pifithrin-l, histone deacetylase 6 inhibitors, metformin, antioxidants, peroxynitrite decomposition catalysts, and anti-inflammatory mediators including interleukin 10. This review hopefully will contribute toward bridging the gap between preclinical research and the development of realistic novel therapeutic strategies to prevent or reverse the devastating neurotoxic effects of chemotherapy on the (peripheral) nervous system. Cancer 2018;124:2289-98.
INTRODUCTION
In 2017, it is estimated that 1.7 million new cases of cancer will have been diagnosed in the United States alone. Despite this grim statistic, the numbers of successful cancer treatments and cancer survivors have increased dramatically over the last decade.
1,2 However, managing cancer-related pain remains challenging. Cancer-related pain can be categorized either as pain related to active tumor growth or as pain resulting from cancer treatment. The latter, when produced by chemotherapeutic agents, often manifests as chemotherapy-induced peripheral neuropathy (CIPN).
reportedly had only limited success 9 ; only the serotoninnorepinephrine reuptake inhibitors duloxetine and venlafaxine have been shown to ameliorate chemotherapy-induced (oxaliplatin or paclitaxel) neuropathic pain in phase 3 placebo-controlled randomized clinical trials. 10, 11 Other agents, including the Ca 21 channel blockers gabapentin and pregabalin and the Na 1 channel blockers carbamazepine and oxcarbazepine, either failed in randomized trials or demonstrated effectiveness only in small, non-placebocontrolled trials. [12] [13] [14] [15] [16] [17] The development of novel treatments to prevent or reverse CIPN is a pressing need that will require an in-depth understanding of the underlying mechanisms.
Herein, we review current knowledge regarding the pathophysiological mechanisms underlying CIPN, with a focus on mitochondrial dysfunction, nitro-oxidative stress, and neuroinflammation. We also describe potential novel avenues for the development of mechanism-based therapeutic strategies for the prevention and treatment of CIPN. A major concern in the development of novel therapeutic strategies is that such agents might interfere with tumor control by the chemotherapeutics. An optimal solution would be to identify agents that protect against CIPN while enhancing tumor control. Therefore, we have focused on candidate agents that have the potential to meet both goals.
Targeting Neuronal Mitochondrial Dysfunction
Mitochondria are double-membrane-bound organelles that function as a cell's "power plant," converting nutrients into the cellular energy "currency" adenosine triphosphate (ATP), primarily through oxidative phosphorylation. In neuronal cells, mitochondrial oxidative phosphorylation produces >90% of the ATP required for maintaining normal cellular activities. Failure of the mitochondria to synthesize adequate amounts of ATP for neuronal activities that require high energy, such as action potential generation, synaptic transmission, and axonal transport, is thought to be one of the prime mechanisms underlying CIPN. 18, 19 A wide array of chemotherapeutic agents that induce CIPN cause mitochondrial dysfunction in peripheral sensory neurons, despite marked differences in the mechanisms via which they exert their antitumor effects. For example, cisplatin and oxaliplatin intercalate mitochondrial DNA, leading to failure in mitochondrial protein synthesis and to mitochondrial dysfunction. 20 Paclitaxel induces opening of the mitochondrial permeability transition pore, which evokes mitochondrial membrane depolarization and Ca 21 release, resulting in vacuolated mitochondria with compromised functionality. 21 Vincristine and bortezomib also dysregulate mitochondrial Ca 21 signaling, leading to defective energy production. [22] [23] [24] Persistent mitochondrial dysfunction generates nitro-oxidative stress (described below), which causes nitro-oxidative damage to mitochondrial DNA and proteins, further aggravating mitochondrial damage and leading to energy deficiency in sensory neurons. 25 Consistent with the mitotoxicity theory of CIPN, swollen and vacuolated mitochondria appear in peripheral nerves and dorsal root ganglion (DRG) neuronal cell bodies in rodent models of peripheral neuropathy induced by paclitaxel, 26, 27 cisplatin, 28 oxaliplatin, 29 bortezomib, 24 or vincristine. 24 These abnormalities in mitochondrial morphology are accompanied by deficiencies in mitochondrial bioenergetics in DRG neurons and peripheral nerves in these models of CIPN. 28, [30] [31] [32] More specifically, impairments in mitochondrial basal respiration, maximal respiration capacity, and ATP production are observed. 28, [30] [31] [32] Chemotherapy-induced mitochondrial dysfunction and the concomitant energy deficits in sensory neurons are believed to lead to the failure of these cells to sustain normal cellular activities, and ultimately to the symptoms of CIPN. For example, the formation of intraepidermal nerve fibers (IENFs) requires nerve fibers originating from subepidermal nerve fiber bundles to traverse the epidermal basal lamina and branch within the epidermis, which is a highly bioenergetically demanding process. 19, 30 In CIPN, the lack of a sufficient energy supply has been proposed to result in the inability of IENFs to sprout within the epidermis 19, 30 and thus to loss of IENFs, a clinical diagnostic marker of CIPN. 33 Mitochondrial deficits also are likely to lead to dysfunction of the Na 1 /K 1 exchanger, a major energy consumer in neuronal cells. 34 Dysfunction of the Na 1 /K 1 exchanger disrupts the electrochemical gradient across the cellular membrane, thereby facilitating spontaneous discharges in sensory neurons, 35 which is another characteristic of CIPN that may well be responsible for the spontaneous shooting and burning pain that many patients report. neurological disorders. 36, 37 Recent studies have indicated that chemotherapeutic agents trigger a similar damage pathway. For example, we demonstrated that cisplatin treatment rapidly increases mitochondrial levels of p53 in DRG neurons, followed by a reduction in mitochondrial membrane potential and ultimately by the disruption of mitochondrial integrity and function. 28 It is interesting to note that we found that the mitochondrial protectant pifithrin-l, which prevents mitochondrial accumulation of p53, also prevented paclitaxel-induced and cisplatininduced neuropathic pain and sensory loss and averted the loss of IENFs in mouse models of CIPN. 27, 28 Pifithrin-l not only prevented CIPN symptoms but also protected against loss of mitochondrial membrane potential, abnormalities in mitochondrial morphology, and functional mitochondrial deficiencies in DRG neurons. 27, 28 It is important to note that because pifithrin-l targets the p53-mitochondrial pathway without affecting the transcriptional functions of p53, 38 it does not negatively affect the tumor-killing effects of chemotherapy. 27, 37 Rather, in vivo studies have shown that pifithrin-l can itself exert antitumor effects. 39 In vitro, the coadministration of pifithrin-l with paclitaxel or cisplatin enhanced tumor cell killing. 27, 40 Taken together, these data suggest that the coadministration of pifithrin-l with chemotherapeutics may represent a promising novel approach with which to improve cancer treatment while protecting against the development of CIPN. 27, 28 Preventing or reversing neuronal mitochondrial abnormalities and CIPN by inhibiting histone deacetylase 6
Pharmacological targeting of histone deacetylase 6 (HDAC6) is another potential therapeutic strategy for CIPN that targets the mitochondrial pathway and has potential antitumor effects. 30, 41, 42 HDAC6 is a class IIB histone deacetylase that has limited effect on histones and acts mainly in the cytosol, in which it deacetylates tubulin, heat shock protein 90, and many other substrates. The neuroprotective effects of HDAC6 inhibitors have been demonstrated in models of neurological disorders, including Alzheimer disease and Charcot-Marie-Tooth disease. [43] [44] [45] The neuroprotective effects of HDAC6 inhibitors in these models are associated with improved mitochondrial axonal transport and reduced oxidative damage. [43] [44] [45] We recently demonstrated that HDAC6 inhibitors prevent cisplatin-induced deficits in axonal mitochondrial transport in primary cultures of DRG neurons. 30 In vivo, the coadministration of an HDAC6
inhibitor with cisplatin prevented cisplatin-induced neuropathic pain.
It is interesting to note that HDAC6 inhibition also has disease-modifying properties. Administration of the HDAC6 inhibitor ACY-1083 after the completion of chemotherapy, when CIPN had fully developed, reversed the mitochondrial bioenergetic deficits in distal peripheral nerves and DRG neurons. 30 Consequently, HDAC6 inhibition reversed all symptoms of CIPN, including mechanical allodynia, spontaneous pain, and sensory loss. HDAC6 inhibitors also stimulated the regrowth of IENFs, presumably through promoting the distribution of bioenergetically functional mitochondria to nerve terminals in which the energy-consuming processes take place. 30 It is important to note that both the preventive and restorative effects of HDAC6 inhibition were maintained for months in mice after the termination of treatment with the HDAC6 inhibitor, highlighting its diseasemodifying effects. 30 Because HDAC6 inhibitors already are in clinical trials testing their potential capacity to increase the efficacy of chemotherapy, they also are of interest as treatment of the neurotoxic side effects of cancer therapy. 41, 42 Additional clinical trials that include the evaluation of CIPN parameters in patients treated with a combination of HDAC6 inhibitors and paclitaxel or cisplatin as a secondary outcome also currently are underway (ClinicalTrials.gov identifiers NCT02632071, NCT02661815, and NCT02856568).
Preventing CIPN by targeting mitochondrial pathways with metformin
Recent preclinical studies have suggested that metformin, a drug approved by the US Food and Drug Administration (FDA) for glycemic control in patients with type 2 diabetes, alleviates neuropathic and inflammatory pain in various models. 46 We demonstrated that metformin also prevents cisplatin-induced neuropathic pain, numbness, and loss of IENFs. 47 Although the exact mechanisms underlying these protective effects need to be delineated, it is likely that metformin acts via modulation of mitochondria-dependent cellular metabolism. Metformin's beneficial effects on energy metabolism include enhanced activity of carnitine palmitoyltransferase 1, an essential component of mitochondrial fatty acid oxidation. 48 Metformin also promoted restoration of mitochondrial membrane potential and reversal of mutationassociated alterations in energy metabolism in a model of Parkinson disease 49 and contributed toward the restoration of cellular energy by activating adenosine monophosphate-activated protein kinase. 50 Our preliminary data have indicated that the coadministration of metformin with cisplatin prevents the neuronal mitochondrial dysfunction that results from cisplatin treatment in a mouse model of CIPN. It is interesting to note that epidemiological studies also have demonstrated an association between metformin use and a decreased occurrence of cancer, 51 suggesting that metformin may have anticancer effects. In addition, metformin has been shown to promote tumor cell death in vitro. [52] [53] [54] Therefore, further exploration of metformin as a potential 2-pronged approach that targets both tumor growth and CIPN is warranted.
Contribution of Nitro-Oxidative Stress to CIPN
Downstream of mitochondrial dysfunction, oxidative stress is another important common pathway that could be targeted to prevent or reverse CIPN. Mitochondria are the most important endogenous source of reactive oxygen species (ROS). Whereas the amount of ROS produced is tightly regulated in intact mitochondria, chemotherapyinduced mitochondrial damage leads to dysregulation of ROS production and the generation of oxidative stress. 55 The peripheral nervous system is especially susceptible to chemotherapy-induced oxidative damage, due to its high content of phospholipids, mitochondria-rich axoplasm, and weak cellular antioxidant defenses. 56 Evidence of the oxidative modification of lipids and proteins in the sciatic nerve and spinal cord has been reported in a rat model of oxaliplatin-induced painful neuropathy. 57 Increased ROS levels in these tissues also were observed during the early development of paclitaxel-induced neuropathic pain. 58 Nitrosative stress has emerged as an additional strong contributor to chemotherapy-induced neuropathic pain. Nitric oxide rapidly reacts with superoxide to form reactive nitrogen species, mainly peroxynitrite, a highly reactive oxidant under physiological conditions. 59 Peroxynitrite inactivates mitochondrial manganese superoxide dismutase (MnSOD), the primary antioxidant enzyme that keeps cellular superoxide levels under control, thereby generating a feed-forward loop of nitro-oxidative stress and mitochondrial dysfunction. 60 CIPN induced by paclitaxel, oxaliplatin, and bortezomib is associated with the nitration and inactivation of MnSOD, accompanied by mitochondrial bioenergetic deficits in peripheral sensory axons. 32 Supporting the pathogenic role of nitro-oxidative stress, experimental strategies targeting ROS and peroxynitrite prevent the development of CIPN in various rodent models. For example, antioxidants such as acetyl-L-carnitine and a-lipoic acid are reported to have prevented mitochondrial damage and the development of neuropathic pain in response to paclitaxel, oxaliplatin, and bortezomib. 24, [61] [62] [63] [64] The free radical scavenger phenyl N-tert-butylnitrone and the superoxide dismutase mimetic TEMPOL ameliorated mechanical allodynia in rats treated with paclitaxel. 65, 66 Mitochondria-targeted antioxidants, such as mitoVitE and melatonin, also attenuated paclitaxel-induced neuropathic pain. 67, 68 However, despite positive results from preclinical studies, results from clinical studies are less satisfying. Clinical trials using nutraceuticals with antioxidant properties, including vitamin E, acetyl-L-carnitine, glutamine, glutathione, vitamin B6, omega-3 fatty acids, and a-lipoic acid, have reported controversial results. 69, 70 For example, acetyl-L-carnitine, despite demonstrating great promise in initial clinical studies, 71 was not found to be effective in later clinical trials and even exacerbated CIPN in some patients. 72, 73 Likewise, in a recent study of 243 patients treated with a-lipoic acid while receiving platinum chemotherapy, the agent demonstrated no protective effects. 74 The failure of these antioxidants to alleviate CIPN might be attributed to their rapidly exhausted antioxidant activity. Moreover, the majority of antioxidants that have been tested clinically were chosen for their availability and safety profiles rather than their strong antioxidant properties. An alternative route to external antioxidant supplementation would be to boost endogenous antioxidant responses. The transcription factor peroxisome proliferator-activated receptor c (PPAR-c) has emerged as a central hub in endogenous responses against oxidative stress. 75 Upregulation of key antioxidant enzymes, including MnSOD and glutathione peroxidase, and enhanced mitochondrial energy metabolism have been observed at the time of PPAR-c activation. 76, 77 It is important to note that the neuroprotective effects of PPAR-c agonists have been reported in various neurological disorders, including nerve injury-induced neuropathic pain and trigeminal neuropathic pain. 78, 79 Given that PPAR-c agonists including pioglitazone and rosiglitazone are approved by the FDA for type 2 diabetes, these agents may be worth investigating for their therapeutic potential in CIPN.
Conversely, therapeutic agents targeting peroxynitrite may be an appealing therapeutic approach. Unlike ROS, whose existence at normal physiological concentrations is necessary for synaptic plasticity and cognitive function, 80 to the best of our knowledge peroxynitrite has no known beneficial effects. Peroxynitrite decomposition catalysts have been shown to block the development of neuropathic pain induced by paclitaxel, oxaliplatin, and bortezomib in rats, through attenuating chemotherapeuticinduced decreases in mitochondrial ATP production. 32, 81 The protective effects were exerted without compromising the antitumor activity of the chemotherapeutic agents.
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Contribution of Neuroinflammation to CIPN
Although the widely accepted concept is that chemotherapeutics are immunosuppressive, recent studies have shown that they actually can enhance the immune response to assist T-cell-mediated killing of tumor cells. 82, 83 In addition, increased levels of circulating proinflammatory cytokines have been reported in patients receiving chemotherapy. 84 It is well known that local or systemic inflammation and the production of proinflammatory cytokines can induce pain. Collectively, these findings suggest that neuroinflammation (ie, inflammation in the peripheral or central nervous tissues) is one of the major contributors to CIPN. Neuroinflammation is characterized by infiltration of immune cells, activation of glial cells, and the production of inflammatory mediators in the nervous system. It is interesting to note that the effects from chemotherapeutic drugs on innate and adaptive immune responses, along with glial cell activation, have been reported in rodent studies of CIPN. 84 In response to chemotherapy-induced damage, intracellular molecules known as damage-associated molecular patterns, such as mitochondrial DNA and high-mobility group box 1, are released and activate the receptor for advanced glycation end product (RAGE) and toll-like receptors (TLRs) on neurons and immune cells infiltrating the DRG, leading to neuroinflammation. 85, 86 It has been proposed that chemotherapeutics such as paclitaxel may directly activate TLRs. In support of a role for TLRs in CIPN, it has been shown that coadministration of a TLR4 antagonist with paclitaxel prevented the development of mechanical allodynia in rats. 87 Similarly, genetic ablation of either TLR4 or TLR3 is reported to protect mice from developing hyperalgesia after treatment with cisplatin. 88 It is interesting to note that, despite previous studies suggesting that spinal cord TLR4 mediates mechanical hypersensitivity in inflammatory and injury-induced neuropathic pain models only in male mice, 89 the development of (TLR4-dependent) cisplatin-induced mechanical allodynia was observed to be present in both male and female mice. 90 To the best of our knowledge, it remains unclear if such sex dimorphism exists in humans with CIPN.
Chemotherapy-induced infiltration of macrophages into the DRG is mediated via the chemoattractants C-C motif chemokine 2 (CCL2) and C-X3-C motif chemokine ligand 1 (CX3CL1). 87, [91] [92] [93] Infiltrating macrophages produce proinflammatory cytokines that can lower the activation threshold of spinal and DRG neurons and lead to hyperexcitability and spontaneous discharges, thereby contributing to pain. 94, 95 In response to these inflammatory stimuli, glial cells (including Schwann cells and satellite cells in the peripheral nervous system and astrocytes in the spinal cord) undergo phenotypic changes and secrete more proinflammatory cytokines and chemokines, further enhancing neuronal excitability and pain hypersensitivity. 84, 96, 97 Blockade of proinflammatory signaling through interleukin 1 receptor antagonist (IL-1ra) and antitumor necrosis factor a (TNF-a) have been shown to attenuate CIPN symptoms in rodents. 96, 98 In addition, depleting macrophages through the administration of clodronate, or blocking macrophage infiltration by the intrathecal administration of CCL2 or CX3CL1 neutralizing antibody, has been reported to prevent CIPN in multiple models. 92, 99 Minocycline, a broad-spectrum antibiotic that inhibits macrophage/microglia activation and proinflammatory cytokine production, prevented oxaliplatininduced and bortezomib-induced mechanical hyperalgesia in rodents. 99, 100 A recent pilot clinical study demonstrated significant reductions in the daily average pain score with the use of minocycline, although it did not fully prevent paclitaxel-induced neuropathy. 101 Further studies are needed to examine the usefulness and safety of minocycline as a preventive intervention for CIPN.
Pharmacological modulation of pathways that control neuroinflammation can mitigate chemotherapyinduced neuropathic pain. For example, rodent studies have shown that orally available A 3 adenosine receptor (A 3 AR) agonists protect against CIPN. These A 3 AR agonists also mitigated spinal neuroinflammatory processes, including astrocyte activation and increases in IL-1b and TNF-a, and blocked neuropathic pain caused by paclitaxel, oxaliplatin, and bortezomib without antagonizing their antitumor effects. 97, 102 Fingolimod, an FDAapproved immunomodulatory drug for the treatment of multiple sclerosis, also prevented neuroinflammation and ameliorated neuropathic pain induced by paclitaxel and oxaliplatin without having a negative impact on their anticancer effects. 103 This drug targets the sphingosine-1-phosphate receptor, thereby antagonizing chemotherapyinduced activation of nuclear factor jB (NF-jB) and enhanced formation of proinflammatory cytokines. suggested that regulatory T cells (Tregs) and cytokines such as IL-10 are needed to recover from CIPN. For example, reduced numbers of Tregs have been reported in models of paclitaxel-induced and oxaliplatin-induced pain. 104, 105 In this regard, boosting the endogenous antiinflammatory state might serve as another route to pain resolution in patients with CIPN. Several studies have demonstrated that boosting the Treg subpopulation through the intrathecal adoptive transfer of Tregs or the administration of the Treg-enhancing bee venom-derived phospholipase A 2 reduces chemotherapy-induced neuropathic pain in rodents. 104, 106 With respect to regulatory cytokines, oxaliplatin-induced mechanohypersensitivity is associated with reduced levels of the anti-inflammatory cytokines IL-10 and IL-4 in the spinal dorsal horn. 107 Conversely, intrathecal IL-10 gene therapy or the intrathecal administration of recombinant IL-10 has been shown to progressively reverse the allodynic state associated with paclitaxel treatment. 96, 108 In vitro, IL-10 suppressed paclitaxel-induced spontaneous discharges in DRG neurons. 108 It is interesting to note that we recently found that spontaneous resolution of CIPN depends on endogenous IL-10 signaling; blocking IL-10 signaling through the intrathecal administration of a neutralizing antibody delayed recovery from CIPN. 108 Consistently, IL-10-deficient mice did not recover from CIPN. These findings indicate that IL-10 signaling is part of the natural resolution pathway for CIPN, and further underscores the therapeutic potential of IL-10 therapy to reverse CIPN. One concern is that enhancing IL-10 levels might suppress the immune response to the tumor; however, evidence has suggested that IL-10 signaling actually may prevent tumor formation and contribute toward the antitumor effects of CD8 1 T cells. Specifically, mice deficient in IL-10 signaling develop tumors spontaneously, and treatment with Figure 1 . Schematic overview of mechanisms underlying chemotherapy-induced peripheral neuropathy and mechanism-based disease interventions. CCL2 indicates C-C motif chemokine 2; CX3CL1, C-X3-C motif chemokine ligand 1; HDAC6, histone deacetylase 6; IL-10, interleukin 10; IENF, intraepidermal nerve fiber; RNS, reactive nitrogen species; ROS, reactive oxygen species; SNRIs, serotonin-norepinephrine reuptake inhibitors.
recombinant IL-10 stimulates the cytotoxicity of tumorresident CD8
1 T cells and promotes long-lasting antitumor immunity. 109 Therefore, reinforcing IL-10 signaling through gene therapy or recombinant IL-10 also may be a promising approach that could simultaneously stimulate antitumor immunity and reverse CIPN.
Conclusions and Future Perspectives
Clinically, various analgesics have been tested in an attempt to control neuropathic pain induced by chemotherapy, with only serotonin-norepinephrine reuptake inhibitors and Ca 21 and Na 1 channel blockers demonstrating limited success. 10, 11, 13, 15, 16 Although the exact mechanisms remain elusive, a central role for mitochondrial dysfunction and nitrooxidative stress in the pathogenesis of CIPN has been identified (Fig. 1) . Preclinical data have demonstrated great promise for compounds targeting this pathway, such as pifithrin-l, HDAC6 inhibitors, and metformin, as well as antioxidants and peroxynitrite decomposition catalysts as prophylactic treatment of CIPN. 24, 27, 30, 47, [61] [62] [63] [64] [65] [66] [67] [68] 110 It is interesting to note that HDAC6 inhibitors were found to be effective in both preventing and reversing CIPN, 30 with reported synergistic effects on tumor killing in combination with chemotherapy. 41, 42 Given these unique features, HDAC6 inhibition may be a preferred treatment option for patients already receiving chemotherapy. Conversely, "repurposing" metformin has the advantage of using an inexpensive drug with a well-known safety profile to actively prevent CIPN, provided it is administered before the first chemotherapy session. Because metformin already is being tested in clinical trials for potential anticancer effects, the rapid evaluation of its preventive effects in CIPN should be achievable. 111 Fingolimod, A 3 AR agonists, and minocycline are candidates for targeting the proinflammatory pathways that contribute to Figure 2 . Site of action of chemotherapeutics and mechanism-based treatments for chemotherapy-induced peripheral neuropathy. CCL2 indicates C-C motif chemokine 2; CX3CL1, C-X3-C motif chemokine ligand 1; DRG, dorsal root ganglion; HDAC6, histone deacetylase 6; IENF, intraepidermal nerve fiber; IL-1b, interleukin-1 beta; IL-10, interleukin 10; SNRI, serotonin-norepinephrine reuptake inhibitors; TNF-a, tumor necrosis factor a.
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97,99,100,107 IL-10 gene therapy or recombinant IL-10 treatment may represent a more efficacious approach to promote recovery from CIPN in both patients with cancer and cancer survivors because it engages natural pain resolution pathways and therefore is likely to have true diseasemodifying effects. 96, 108 Preclinical studies have identified novel potential targets for mechanism-based preventive and curative interventions for CIPN (Fig. 2) . Clinical trials currently are underway to focus not only on symptom relief, but also on mechanism-based preventive and curative interventions.
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